Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study

The purpose of this trial was to study feasibility and tolerance of a dose-intensive multicyclic alternating induction chemotherapy with repeated stem cell support in a series of 43 metastatic breast cancer patients. Anthracycline-naive patients (n = 21) received cyclophosphamide 2.5 g/m2 plus doxor...

Descripción completa

Detalles Bibliográficos
Autores: Garcia-Rayo, S. (S.)|||/items/5872c5cf-c545-4aaa-9448-d3d626e399db, Perez-Calvo, J. (Javier)|||/items/638f8bcc-03df-440c-9aec-62a991b95b24, Martin-Algarra, S. (Salvador)|||/items/2fba8e8b-e087-4ab0-82e3-a4d157f1e0cc, Martinez-Monge, R. (Rafael)|||/items/4f936ddc-91ab-4824-b659-c6c6dab6698b, Fernandez-Hidalgo, Ó. (Óscar)|||/items/81d33bbe-62df-4d48-aeb0-d07f3b1b16a6, Subira, L. (L.)|||/items/24b38dc2-d9af-4635-94d3-6a80723db262, Martinez-Aguillo, M. (M.)|||/items/1a956353-bfc8-4100-896e-781680752477, Rebollo, J. (J.)|||/items/cb3e037c-8404-4b0f-9ca1-d807fbd5c02c, Azinovic, I. (Ignacio)|||/items/44d8f3ec-afbe-47c7-962b-fb1ddb5da68e, Brugarolas, A. (A.)|||/items/172258ec-bf10-4b35-a5e8-9ad2953a8559
Tipo de recurso: artículo
Fecha de publicación:2001
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/22736
Acceso en línea:https://hdl.handle.net/10171/22736
Access Level:acceso abierto
Palabra clave:Dose-intensity
Breast cancer
Peripheral blood stem cells
id ES_3e1ab142ae893d6d82ae8d06134faaba
oai_identifier_str oai:dadun.unav.edu:10171/22736
network_acronym_str ES
network_name_str España
repository_id_str
spelling Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility studyGarcia-Rayo, S. (S.)|||/items/5872c5cf-c545-4aaa-9448-d3d626e399dbPerez-Calvo, J. (Javier)|||/items/638f8bcc-03df-440c-9aec-62a991b95b24Martin-Algarra, S. (Salvador)|||/items/2fba8e8b-e087-4ab0-82e3-a4d157f1e0ccMartinez-Monge, R. (Rafael)|||/items/4f936ddc-91ab-4824-b659-c6c6dab6698bFernandez-Hidalgo, Ó. (Óscar)|||/items/81d33bbe-62df-4d48-aeb0-d07f3b1b16a6Subira, L. (L.)|||/items/24b38dc2-d9af-4635-94d3-6a80723db262Martinez-Aguillo, M. (M.)|||/items/1a956353-bfc8-4100-896e-781680752477Rebollo, J. (J.)|||/items/cb3e037c-8404-4b0f-9ca1-d807fbd5c02cAzinovic, I. (Ignacio)|||/items/44d8f3ec-afbe-47c7-962b-fb1ddb5da68eBrugarolas, A. (A.)|||/items/172258ec-bf10-4b35-a5e8-9ad2953a8559Dose-intensityBreast cancerPeripheral blood stem cellsThe purpose of this trial was to study feasibility and tolerance of a dose-intensive multicyclic alternating induction chemotherapy with repeated stem cell support in a series of 43 metastatic breast cancer patients. Anthracycline-naive patients (n = 21) received cyclophosphamide 2.5 g/m2 plus doxorubicin 80 mg/m2 alternating every 14 days with paclitaxel 200-350 mg/m2 plus cisplatin 120 mg/m2. Patients who had previously received anthracyclines (n = 22) received cisplatin 120 mg/m2 plus etoposide 600 mg/m2 alternating with paclitaxel 200-350 mg/m2 plus ifosfamide 8 g/m2. Peripheral blood stem cells were infused after every course except the first, with a median CD34+ dose of 2.1 ´ 106/kg per cycle. Positive selection of CD34+ cells was performed in good mobilizers. The median number of cycles administered was six (4-8), and the time interval between them was 17 days. Median summation dose intensities (SDI) actually administered for the CA-TP and PE-TI protocol were 4.95 and 4.69, respectively (87% of scheduled SDI). There were 15 complete (35%) and 21 partial responses (49%), for an overall response rate of 84% (95% CI, 73%-95%). Infection or neutropenic fever occurred in 50% of the cycles. There was one treatment-related death. After a median follow-up of 26 months, the median event-free-survival was 12 months (95% CI: 10-14) and overall survival was 31 months. These high dose-intensity induction treatments seem to be feasible with sequential stem cell support.NatureDadun. Depósito Académico Digital Universidad de Navarra20122012-06-2920012001-01-0120012001-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/22736reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/227362026-06-21T12:47:57Z
dc.title.none.fl_str_mv Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study
title Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study
spellingShingle Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study
Garcia-Rayo, S. (S.)|||/items/5872c5cf-c545-4aaa-9448-d3d626e399db
Dose-intensity
Breast cancer
Peripheral blood stem cells
title_short Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study
title_full Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study
title_fullStr Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study
title_full_unstemmed Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study
title_sort Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study
dc.creator.none.fl_str_mv Garcia-Rayo, S. (S.)|||/items/5872c5cf-c545-4aaa-9448-d3d626e399db
Perez-Calvo, J. (Javier)|||/items/638f8bcc-03df-440c-9aec-62a991b95b24
Martin-Algarra, S. (Salvador)|||/items/2fba8e8b-e087-4ab0-82e3-a4d157f1e0cc
Martinez-Monge, R. (Rafael)|||/items/4f936ddc-91ab-4824-b659-c6c6dab6698b
Fernandez-Hidalgo, Ó. (Óscar)|||/items/81d33bbe-62df-4d48-aeb0-d07f3b1b16a6
Subira, L. (L.)|||/items/24b38dc2-d9af-4635-94d3-6a80723db262
Martinez-Aguillo, M. (M.)|||/items/1a956353-bfc8-4100-896e-781680752477
Rebollo, J. (J.)|||/items/cb3e037c-8404-4b0f-9ca1-d807fbd5c02c
Azinovic, I. (Ignacio)|||/items/44d8f3ec-afbe-47c7-962b-fb1ddb5da68e
Brugarolas, A. (A.)|||/items/172258ec-bf10-4b35-a5e8-9ad2953a8559
author Garcia-Rayo, S. (S.)|||/items/5872c5cf-c545-4aaa-9448-d3d626e399db
author_facet Garcia-Rayo, S. (S.)|||/items/5872c5cf-c545-4aaa-9448-d3d626e399db
Perez-Calvo, J. (Javier)|||/items/638f8bcc-03df-440c-9aec-62a991b95b24
Martin-Algarra, S. (Salvador)|||/items/2fba8e8b-e087-4ab0-82e3-a4d157f1e0cc
Martinez-Monge, R. (Rafael)|||/items/4f936ddc-91ab-4824-b659-c6c6dab6698b
Fernandez-Hidalgo, Ó. (Óscar)|||/items/81d33bbe-62df-4d48-aeb0-d07f3b1b16a6
Subira, L. (L.)|||/items/24b38dc2-d9af-4635-94d3-6a80723db262
Martinez-Aguillo, M. (M.)|||/items/1a956353-bfc8-4100-896e-781680752477
Rebollo, J. (J.)|||/items/cb3e037c-8404-4b0f-9ca1-d807fbd5c02c
Azinovic, I. (Ignacio)|||/items/44d8f3ec-afbe-47c7-962b-fb1ddb5da68e
Brugarolas, A. (A.)|||/items/172258ec-bf10-4b35-a5e8-9ad2953a8559
author_role author
author2 Perez-Calvo, J. (Javier)|||/items/638f8bcc-03df-440c-9aec-62a991b95b24
Martin-Algarra, S. (Salvador)|||/items/2fba8e8b-e087-4ab0-82e3-a4d157f1e0cc
Martinez-Monge, R. (Rafael)|||/items/4f936ddc-91ab-4824-b659-c6c6dab6698b
Fernandez-Hidalgo, Ó. (Óscar)|||/items/81d33bbe-62df-4d48-aeb0-d07f3b1b16a6
Subira, L. (L.)|||/items/24b38dc2-d9af-4635-94d3-6a80723db262
Martinez-Aguillo, M. (M.)|||/items/1a956353-bfc8-4100-896e-781680752477
Rebollo, J. (J.)|||/items/cb3e037c-8404-4b0f-9ca1-d807fbd5c02c
Azinovic, I. (Ignacio)|||/items/44d8f3ec-afbe-47c7-962b-fb1ddb5da68e
Brugarolas, A. (A.)|||/items/172258ec-bf10-4b35-a5e8-9ad2953a8559
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv Dose-intensity
Breast cancer
Peripheral blood stem cells
topic Dose-intensity
Breast cancer
Peripheral blood stem cells
description The purpose of this trial was to study feasibility and tolerance of a dose-intensive multicyclic alternating induction chemotherapy with repeated stem cell support in a series of 43 metastatic breast cancer patients. Anthracycline-naive patients (n = 21) received cyclophosphamide 2.5 g/m2 plus doxorubicin 80 mg/m2 alternating every 14 days with paclitaxel 200-350 mg/m2 plus cisplatin 120 mg/m2. Patients who had previously received anthracyclines (n = 22) received cisplatin 120 mg/m2 plus etoposide 600 mg/m2 alternating with paclitaxel 200-350 mg/m2 plus ifosfamide 8 g/m2. Peripheral blood stem cells were infused after every course except the first, with a median CD34+ dose of 2.1 ´ 106/kg per cycle. Positive selection of CD34+ cells was performed in good mobilizers. The median number of cycles administered was six (4-8), and the time interval between them was 17 days. Median summation dose intensities (SDI) actually administered for the CA-TP and PE-TI protocol were 4.95 and 4.69, respectively (87% of scheduled SDI). There were 15 complete (35%) and 21 partial responses (49%), for an overall response rate of 84% (95% CI, 73%-95%). Infection or neutropenic fever occurred in 50% of the cycles. There was one treatment-related death. After a median follow-up of 26 months, the median event-free-survival was 12 months (95% CI: 10-14) and overall survival was 31 months. These high dose-intensity induction treatments seem to be feasible with sequential stem cell support.
publishDate 2001
dc.date.none.fl_str_mv 2001
2001-01-01
2001
2001-01-01
2012
2012-06-29
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10171/22736
url https://hdl.handle.net/10171/22736
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Nature
publisher.none.fl_str_mv Nature
dc.source.none.fl_str_mv reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra
instname:Universidad de Navarra
instname_str Universidad de Navarra
reponame_str Dadun. Depósito Académico Digital de la Universidad de Navarra
collection Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406504013004800
score 15,301603